Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Antioxidant Treatment of Type 2 Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00609102
First received: January 23, 2008
Last updated: March 15, 2011
Last verified: March 2011

January 23, 2008
March 15, 2011
July 2008
July 2011   (final data collection date for primary outcome measure)
Blood glucose [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00609102 on ClinicalTrials.gov Archive Site
HbA1c levels [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Antioxidant Treatment of Type 2 Diabetes
Not Provided

This study examines whether an antioxidant taken orally will improve glucose tolerance and insulin secretion in type 2 diabetic subjects.

Not Provided
Interventional
Phase 0
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Diabetes Mellitus, Non-Insulin-Dependent
  • Drug: Placebo
    one capsule BID
  • Drug: n-aceylcysteine
    450 mgm BID
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Active Comparator: antioxidant drug
    n-acetylcysteine
    Intervention: Drug: n-aceylcysteine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
90
Not Provided
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria: Subjects with a known diagnosis of type 2 diabetes -

Exclusion Criteria: None, except known intolerance to n-acetylcysteine

-

Both
18 Years to 70 Years
Yes
Contact: R Paul Robertson, MD 206-726-1210 rpr@pnri.org
United States
 
NCT00609102
Antioxidant trmt type 2, NIH R01 38325-19
Not Provided
R. Paul Robertson, Pacific Northwest Research Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP